Related references
Note: Only part of the references are listed.Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
Leonard Saltz et al.
CLINICAL COLORECTAL CANCER (2012)
The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial
D. P. Modest et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari et al.
CLINICAL CANCER RESEARCH (2011)
Anti-EGFR therapy in first-line colorectal cancer
Maria J. Lamas et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
Eric Assenat et al.
ONCOLOGIST (2011)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis
E. S. K. Ma et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco et al.
ONCOGENE (2003)
K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
M Brink et al.
CARCINOGENESIS (2003)
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor
J Schlessinger
CELL (2002)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)